Interní Med. 2019; 21(2): 105-109

If a fixed combination, then a fixed combination!

MUDr. Jaroslav Brotánek
Interní oddělení Thomayerovy nemocnice, Praha
1. lékařská fakulta UK, Praha

The article presents a clinical case report on the experience with the use of a novel fixed combination of the β-blocker bisoprolol
and the ACE inhibitor perindopril. A wide range of indications for administering this drug is highlighted. Also, given the presence of a
β-blocker in this combination, we focus on some “myths” that may be associated with the treatment with this particular drug group.

Keywords: hypertension, ACE inhibitors, beta blockers

Published: May 10, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brotánek J. If a fixed combination, then a fixed combination! Interní Med. 2019;21(2):105-109.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hradec J. Skutečně máme v léčbě hypertenze zatratit beta-blokátory? Kapitoly kardiol prakt lék 2010; 2: 105-109. Go to original source...
    2. Widimský J. Současné postavení beta-blokátorů v léčbě hypertenze. Postgraduální med 2010; 12: 929-934.
    3. Widimský J, Widimský J jr. Farmakoterapie hypertenze. Praha: Maxdorf, 2016.
    4. Widimský J jr, Widimský J, et al. Hypertenze. Praha: Triton, 2014.
    5. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in Old Patients with Hypertension. (STOP-Hypertension). Lancet 1991; 338: 1281-1285. Go to original source... Go to PubMed...
    6. National Institute for Health and clinical Excelence. Hypertension management of hypertension in adults in primary care [online]. NICE/BHS, 2006. Dostupné z: www. nice.org.uk/CG034
    7. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    8. Dahlöf B, Sever PS, Poulter NR, et al.; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    9. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-553. Go to original source... Go to PubMed...
    10. Pepine CJ, Handberg EM, Cooper-Dehoff RM, et al.; for the INVEST Investigators. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...
    11. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-2141. Go to original source... Go to PubMed...
    12. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009; 3: CD 001841. Go to original source... Go to PubMed...
    13. Law MH, Morfia JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009; 338: 1665-1683. Go to original source... Go to PubMed...
    14. Riziko plynoucí z tachykardie neroste s tepovou frekvencí lineárně. Med Trib 2015; 11(5): B7-B8.
    15. Léčba kardiaků by se měla opírat o ko plexní korekci rizikových faktorů. Med Trib 2015; 11: B8.
    16. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821. Go to original source... Go to PubMed...
    17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1281-1357. Go to original source... Go to PubMed...
    18. Holman RR, Paul SK, Bethel MA, et al. Long-termfollow-up after tight kontrol of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1575. Go to original source... Go to PubMed...
    19. Sova M, Kamasová M, Václavík J, et al. Betablokátory a chronická obstrukční nemoc. Vnitř Lék 2016; 62: 305-307. Go to PubMed...
    20. Salpeter S, Ormiston T, Salpeter E, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; 2: CD003566. Go to original source... Go to PubMed...
    21. Bhatt SP, Wells JM, Kinney GI, et al. ?-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71: 8-14. Go to original source... Go to PubMed...
    22. Mayer O jr. Jaká je současná pozice betablokátorů v sekundární prevenci ischemické choroby srdeční? Med promoci 2017; 18: 280-2784.
    23. Farmakoterapie chronického srdečního selhání: jak vybrat správný beta-blokátor? Med Trib 2015; 11: B8.
    24. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihyperensive drugs. Am J Hypertens 2007; 20: 311-318. Go to original source... Go to PubMed...
    25. Sabido M, Hohenberger T, Grassi G. Pharmacological intervention in hypertension using beta-blockers: Real-world evidence for long-term effectiveness. Pharmacol Res 2018; 130: 191-197. Go to original source... Go to PubMed...
    26. Rana R, Patil A. Efficacy and safety bi oprolol plus amlodipine fixed dose combination in essential hypertension. The Ind Pract 2008; 61: 225-234.
    27. Wai B, Kearney LG, Hare DL, et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 2012; 11: 14. Go to original source... Go to PubMed...
    28. DiNicolantonio JJ, Lavie CD, O'Keefe JD. Not all Angiotensin-converting enzyme inhibitors are equal: focus on Ramipril and Perindopril. Postgraduate Medicine 2013; 125: 154-168. Go to original source... Go to PubMed...
    29. Myers MG. Use of trough:peak ratio in the assessment of antihypertensive drug therapy. Can J Cardiol 1994;10(Suppl D): 17D-20D. Go to PubMed...
    30. PROGRESS Collaborative Study Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041. Go to original source... Go to PubMed...
    31. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;doi:10.1093/eurheartj/ehy339. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.